CFRXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CFRXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of ContraFect is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, ContraFect's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ContraFect's Risk Assessment distribution charts can be found below:
* The bar in red indicates where ContraFect's Risk Assessment falls into.
ContraFect (OTCPK:CFRXQ) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of ContraFect's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Jane F Barlow | director | 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487 |
Lishan Aklog | director | 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171 |
Michael Messinger | officer: VP Finance | 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534 |
Cary Sucoff | director | 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904 |
David N. Low | director | EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111 |
Sol J Barer | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Lisa Ricciardi | director | C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577 |
Joshua B Muntner | officer: SVP Business Development | 30 FIFTH AVENUE, 12F, NEW YORK NY 10011 |
Shanghai Fosun Pharmaceutical (group) Co., Ltd. | 10 percent owner | BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233 |
Fosun Industrial Co., Ltd | 10 percent owner | FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000 |
Cara M Cassino | officer: Chief Medical Officer | 757 STONY POINT ROAD, BENSON VT 05743 |
Natalie Bogdanos | officer: General Counsel | 207-23 DARREN DRIVE, BAYSIDE NY 11360 |
Roger Pomerantz | director | 711 HARVEST HILL ROAD, CHALFONT PA 18914 |
Michael J. Otto | director | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 06-08-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By GuruFocusNews GuruFocusNews • 07-06-2022
By PurpleRose PurpleRose • 07-15-2022
By GuruFocusNews GuruFocusNews • 06-24-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By PRNewswire PRNewswire • 02-27-2023
By Marketwired • 10-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.